---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-094341"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:30:24.245281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports Q2 net loss $38.5M, cash $431.5M, restarts Phase 3 trials

## Summary
- Interim Phase 2 REGEN-007 data show kidney function stabilization for 18 months in diabetes/advanced CKD patients.
- Manufacturing restarted; QP Declaration of Equivalence received in July; PROACT 1 and 2 trials resumed.
- Closed $140M upsized equity offering in June, extending cash runway into mid-2026.
- Cash & equivalents $431.5M at June 30, 2024 (vs $363.0M Dec 31, 2023).
- R&D expenses $29.4M (Q2 2024) vs $26.4M (Q2 2023); net loss $38.5M vs $34.8M.

## SEC filing metadata
- accession: 0000950170-24-094341
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017024094341/0000950170-24-094341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017024094341/prok-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-094341
- JSON: https://secwatch.observer/filing/0000950170-24-094341.json
- Plain text: https://secwatch.observer/filing/0000950170-24-094341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.